SCIENTIFIC COMMITTEE ON CONSUMER SAFETY (SCCS)

Request for a scientific opinion: β-Arbutin (CAS 497-76-7) with the chemical name 4-hydroxy-phenyl-β-D-glucopyranoside

1. Background
Submission I for β-Arbutin (CAS 497-76-7; EC 207-850-3) with the chemical name 4-hydroxyphenyl-β-D-glucopyranoside and the INCI name Arbutin was submitted in July 2005 by COLIPA.

The effect of Arbutin seems to be due to the fact that it hydrolyses to Hydroquinone. However, Hydroquinone (CAS 123-31-9) is listed in Annex II/1339 of the Cosmetic Regulation No 1223/2009; it means it is banned as cosmetic ingredient with the exception of entry 14 in Annex III. Its permitted use is restricted to professional use in artificial nail systems in a concentration in the final product up to 0.02%. Since Hydroquinone could not be used as a skin whitener after introduction of a ban, other substances have been used for that purpose, including Arbutin.

The first opinion (SCCP/1158/08) on beta-arbutin was adopted the 15 April 2008 with the conclusion: "Although the general toxicological assessment of β-arbutin suggests that the substance may be safe, the bioavailability of hydroquinone under conditions of intended use of the substance is of concern. Whereas hydroquinone was initially permitted at a concentration of 2%, a 1998 opinion of the SCCNFP recommended that the substance should not be used any more as a depigmentating agent in cosmetic products due to observed clinical side effects, among which exogenous ochronosis [41].

Consequently, the SCCP considers the currently requested use of β-arbutin in cosmetic products unsafe. In addition, it is the opinion of the SCCP that the same concern can be expressed for other products that result in the release and/or formation of hydroquinone before or upon application on the skin."

The substance is used as a chemical ingredient alone and as a component of plant extracts like Arctostaphylos Uva Ursi, Vaccinium Vitis-Idaea, Chimaphila Umbellata etc, all rich in content of arbutin, according to the information on skin lightening products available to the Commission Services.

The current submission II is a response to the first opinion on beta-Arbutin.

2. Terms of reference
(1) Does the SCCS consider on the basis of the provided scientific data, the use of β-arbutin to be safe for consumers in cosmetic products in a concentration up to 7% in face creams?

(2) Does the SCCS have any further scientific concerns with regard to the use of β-arbutin in cosmetic products?

3. Deadline:

4. Supporting documents